Pharmacological strategy for congenital myasthenic syndrome with CHRNE mutations: a meta-analysis of case reports.

CONCLUSIONS: This meta-analysis provides evidence that (1) β2-adrenergic receptor agonist therapy could be the first choice of pharmacological strategy for treating CMS with CHRNE mutations; (2) a single-drug-regime, rather than a combination therapy, should be the first choice of treatment; and (3) it is never too late to initiate pharmacological treatment.
PMID: 32727330 [PubMed - as supplied by publisher]

Source: Current Neuropharmacology - July 27, 2020 Category: Drugs & Pharmacology Authors: Huang K, Luo YB, Bi FF, Yang H Tags: Curr Neuropharmacol Source Type: research